Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
BBIO Stock Chart & Stats
$68.54
-$0.10(-0.35%)
At close: 4:00 PM EST
$68.54
-$0.10(-0.35%)
Day’s Range― - ―
52-Week Range$28.33 - $84.94
Previous CloseN/A
Volume379.31K
Average Volume (3M)2.90M
Market Cap
$13.29B
Enterprise Value$15.45B
Total Cash (Recent Filing)$587.48M
Total Debt (Recent Filing)$2.73B
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Apr 30, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding193,862,870
10 Day Avg. Volume2,321,109
30 Day Avg. Volume2,904,035
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)-7.27
Price to Sales (P/S)30.05
P/FCF Ratio-33.75
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue30.76
Enterprise Value/Gross Profit32.60
Enterprise Value/Ebitda-24.81
Forecast
1Y Price Target
$103.65Price Target Upside51.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-1.91
Revenue Forecast (FY)$914.15M
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyUpdated Phase III FORTIFY results showed consistent and statistically significant improvements in functional outcomes and biomarkers for BBP-418 versus placebo, supporting a disease‑modifying profile that could strengthen regulatory submissions and differentiate the product commercially.
Commercial MomentumAttruby's accelerating prescription growth, expanding prescriber base, and patient persistence above historical benchmarks indicate strong market adoption and potential for durable revenue as the franchise scales.
Pipeline Diversification And Regulatory PathwayMultiple late-stage programs including encaleret, infigratinib, and ribitol, along with special regulatory designations and a straightforward path toward submissions, increase the chance of additional approvals and new revenue streams.
Bears Say
Generic Competition RiskPotential generic tafamidis competition could erode pricing power and market share for transthyretin therapies, creating downward pressure on revenue assumptions for the company's franchise.
Regulatory And Execution RiskRegulatory approvals rely on the timing and outcomes of submissions and agency interactions, which introduces execution risk that could delay launches or alter expected label and pricing dynamics.
Transparency And Cash BurnCessation of disclosure on new patient starts combined with high operating expenses from commercialization and R&D sustains significant cash burn and reduces visibility into ongoing uptake, increasing financing and valuation risk.
BridgeBio Pharma News
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $28.32 and its highest was $84.94 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
BridgeBio Pharma Inc’s market cap is $13.29B.
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is Apr 30, 2026 which is in 39 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on Feb 24, 2026. The company reported -$1 earnings per share for the quarter, missing the consensus estimate of -$0.713 by -$0.287.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate is -0.68.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 193,862,870 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -$1 in its last earnings report, missing expectations of -$0.713. Following the earnings report the stock price went down -2.591%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Currently, no hedge funds are holding shares in BBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$103.65 (51.23% Upside)
$103.65 (51.23% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.12%
12-Months-Change
Fundamentals
Return on Equity
39.18%
Trailing 12-Months
Asset Growth
1.82%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
BBIO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive outlook driven by robust commercial momentum for Atruby, multiple positive Phase 3 readouts (notably infigratinib in achondroplasia), improving cash runway via convertible notes, and a clear path to becoming cash-generative by 2028. These progress points materially de-risk the pipeline and support substantial future value creation. Near-term headwinds include a sizable SG&A and operating expense ramp as the company builds commercial infrastructure, continued net cash consumption during the scale-up phase, concentrated current revenue in one product, and external IP/legal uncertainty around tafamidis that has contributed to share-price volatility. Overall, the positives (strong revenue growth, multiple successful late-stage readouts, solid balance sheet actions, and clear launch plans) outweigh the lowlights, though execution and legal risks remain.View all BBIO earnings summariesBBIO Stock 12 Month Forecast
Average Price Target
$103.65
▲(51.23% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Moderna
―
Ownership Overview
20.53% Insiders
24.46% Mutual Funds
40.06% Other Institutional Investors
0.29% Public Companies and Individual Investors